Literature DB >> 9066639

Interleukin-6 production in primary histoculture by normal human kidney and renal tumor tissues.

S G Chang1, S J Lee, S J Lee, J I Kimi, J C Jung, J H Kim, R M Hoffman.   

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine with many biologic activities in vitro, including synergistic or antagonistic actions with one or more other cytokines. The role and induction parameters of IL-6 in renal cell carcinoma (RCC) are not fully understood. To understand the ability of RCC to produce IL-6, we determined the IL-6 concentration in the supernatant of histocultured human normal kidney, RCC, renal Wilms' tumor and renal oncocytoma. From these studies, we conclude that the kidney is one of the main sources of IL-6. Normal renal cortical tissues and renal tumors can produce IL-6 in histoculture without stimulation. Thus histoculture supports the long-term production of IL-6, potentially allowing many important studies of this cytokine in the normal and malignant kidney.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066639

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Juvenile Granulosa Cell Tumor with Elevated Peripheral Interleukin-6 Level Shows Prolonged Fever and Delayed Puberty.

Authors:  Keisuke Okuno; Naohiro Yoneda; Rei Nishimura; Hitoshi Sano; Jun-Ichi Ueyama; Hiroaki Komatsu; Tasuku Harada; Michiko Matsushita; Satoshi Kuwamoto; Yasushi Horie; Susumu Kanzaki
Journal:  Yonago Acta Med       Date:  2019-09-13       Impact factor: 1.641

2.  IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity.

Authors:  I Kryczek; M Gryboś; L Karabon; A Klimczak; A Lange
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

3.  Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma.

Authors:  N Yoshida; S Ikemoto; K Narita; K Sugimura; S Wada; R Yasumoto; T Kishimoto; T Nakatani
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.